The safety of brodalumab for the treatment of psoriasis

• Published in: Expert opinion on drug safety Vol. 19; no. 4; p. 365
• Main Authors: Iznardo, Helena, Puig, Lluís
• Format: Journal Article
• Language: English
• Published: England 02.04.2020
• Subjects: Animals; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Dermatologic Agents - administration & dosage; Dermatologic Agents - adverse effects; Humans; Psoriasis - drug therapy; Psoriasis - pathology; Receptors, Interleukin-17 - antagonists & inhibitors; Severity of Illness Index; treatment; interleukin-17 inhibitors; Biologics; psoriasis; safety; IL-17; brodalumab
• ISSN: 1744-764X
• DOI: 10.1080/14740338.2020.1730326

: Brodalumab is a newly developed targeted biologic agent for the treatment of psoriasis that blocks IL-17 receptor A. : This review sought to provide a detailed overview on safety of brodalumab for the treatment of psoriasis. A PubMed search was conducted for relevant literature. Here we review the efficacy and safety data from key phase II, phase III and open-label extension clinical trials, as well as systematic reviews and meta-analyses. : The unique mechanism of action of brodalumab offers advantages on efficacy over other targeted treatments, with a quick onset of action and long-term maintenance of treatment response. Brodalumab has a favorable safety profile, similar to other IL-17 inhibitors. Infections, especially mucocutaneous candidiasis, must be monitored. Suicidal ideation was detected in brodalumab trials, although a causal relationship has not been revealed. Brodalumab is a highly efficacious and comparably safe therapeutic choice in patients with moderate to severe psoriasis, especially when rapid control of the disease is desired.